NCEL

+ Watchlist + Portfolio

NewcelX Ltd.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.95
52-Week Range: $1.83 – $19.80
Market Cap: $16.46M
P/E (TTM): 5.48
EPS (TTM): 0.52
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.54
PEG Ratio: —
Return on Equity: —
Return on Assets: -49.59%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.40
Debt/Equity: 0.06
Total Debt: $392.00K
Free Cash Flow: $-12.32M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $15.03M

NCEL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Gross Profit	$0.00	$0.00	$0.00	—
Research & Development	$4.28M	$1.61M	$992.00K	$1.13M
Selling, General & Admin	$1.88M	$1.41M	$805.00K	$1.35M
Operating Expenses	$6.25M	$3.02M	$1.80M	$2.47M
Operating Income	-$6.25M	-$3.02M	-$1.80M	-$2.47M
EBITDA	-$5.87M	-$2.47M	-$1.74M	-$2.24M
Pretax Income	-$6.49M	-$3.33M	-$7.20M	-$8.30M
Income Tax	-$47.39K	-$52.68K	-$8.21K	—
Net Income	-$6.45M	-$3.33M	-$7.20M	-$8.30M
Diluted EPS	-2.59	-1.13	-2.43	-2.16
Diluted Shares	2.49M	2.96M	2.96M	3.84M

NCEL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.81M	$1.09M	$650.00K	$2.20M
Receivables	$221.34K	$416.46K	$68.44K	—
Current Assets	$2.10M	$1.53M	$780.00K	$3.18M
Total Assets	$3.54M	$2.20M	$903.00K	$11.45M
Current Liabilities	$2.99M	$3.35M	$8.90M	$4.20M
Long-Term Debt	$0.00	$834.00K	—	—
Total Debt	$2.02M	$2.62M	$2.67M	$355.00K
Total Liabilities	$3.45M	$3.35M	$8.90M	$4.20M
Retained Earnings	-$66.86M	-$65.23M	-$76.59M	-$84.89M
Shareholders' Equity	$92.51K	-$1.15M	-$8.00M	$7.25M
Working Capital	-$884.51K	-$1.82M	-$8.12M	-$1.01M
Net Debt	—	$1.18M	$2.02M	—

NCEL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$5.67M	-$3.44M	-$1.07M	-$2.77M
Capital Expenditure	-$181.61K	-$6.00K	-$6.00K	-$8.00K
Free Cash Flow	-$5.86M	-$3.45M	-$1.07M	-$2.77M
Depreciation & Amortisation	$550.51K	$620.00K	$413.00K	$55.00K
Stock-Based Compensation	$230.42K	$149.00K	$208.00K	$765.00K
Investing Cash Flow	-$186.15K	$103.00K	-$6.00K	$1.70M
Financing Cash Flow	$1.06M	$2.85M	$450.00K	$2.63M
Net Change in Cash	-$4.80M	-$492.00K	-$622.00K	$1.56M

NCEL Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q2 2025	Q4 2025	Q2 2026
Cash & Equivalents	$650.00K	$297.89K	$2.20M	$710.00K
Receivables	$68.44K	$55.56K	—	—
Current Assets	$780.00K	$353.45K	$3.18M	$1.45M
Total Assets	$903.00K	$459.25K	$11.45M	$9.70M
Current Liabilities	$8.90M	$15.49M	$4.20M	$3.66M
Total Debt	$2.67M	$2.54M	$355.00K	$392.00K
Total Liabilities	$8.90M	$15.49M	$4.20M	$3.66M
Retained Earnings	-$76.59M	-$92.95M	-$84.89M	-$90.48M
Shareholders' Equity	-$8.00M	-$15.03M	$7.25M	$6.04M
Working Capital	-$8.12M	-$15.13M	-$1.01M	-$2.21M
Net Debt	$2.02M	$2.24M	—	—

Market Snapshot

About

NewcelX Ltd. is a biotechnology company developing cell therapy technologies and regenerative medicine solutions. The company focuses on novel approaches to cellular therapeutics and tissue engineering applications.